Alternative sweeteners are widely advocated and used. However, there is insufficient scientific information to determine whether alternative sweeteners are of value in the management of diabetes, either in improving dietary adherance or in contributing to the achievement or maintenance of a lower body weight. Each of the available sweeteners has advantages and disadvantages; no one is preferred. Recommendations about alternative-sweetener use should be tailored to the specific dietary and life-style patterns of the individual. Diabetes Care 11:174-82, 1988 S ucrose, glucose, and foods containing large amounts of the two refined sugars have been restricted in various dietary approaches throughout the history of diabetes therapy (1), particularly throughout much of this century, as a means of limiting excursions of blood glucose. (Simple sugars in the form of fruits, vegetables, and dairy products have variably been excluded from this practice.) Consequently, alternative sweeteners, both caloric (fructose, sorbitol, mannitol) and noncaloric (saccharin, aspartame, cyclamate), have played a dominant role in the provision of sweetness in diabetic diets. Despite this, many questions about their use remain. Are alternative sweeteners actually of any value in the management of diabetes? Do they help people with diabetes adhere to their diabetic diets? Do they help in the treatment of the obesity associated with type II (non-insulin-dependent) diabetes? What are the side effects of the different sweet-
ener alternatives? Are such sweeteners safe? Is there one preferable sweetener? What are the parameters of use that will ensure potential benefit without negative side effects or outcomes? Few of these questions have definitive answers that are supportable by research findings. This article outlines the key questions, the available information and research findings, and the apparent conclusions.
Perhaps the first question that should be posed is whether alternative sweeteners are actually of any value in the management of diabetes. Does the availability of alternative sweeteners contribute to adherance to a diabetic diet or to weight-reduction programs for the individual with type II diabetes? Unfortunately, there are few answers. One survey found that 72% of mothers of diabetic children believed that the use of alternative sweeteners and foods helped their children adhere to their diabetic diets (2) . Another survey of 500 people with diabetes found that only 17% felt no craving for sweetness (3) . The remaining 83% revealed that if no alternative sweeteners were available, they would use sucrose. In 1977, it was estimated that 91 % of all people with diabetes used saccharin, which reflects a high demand for sweetener alternatives (4) . However, there are few studies that have investigated the value of noncaloric sweeteners in improving dietary adherance. One study found no evidence that the use of nonnutritive sweeteners improved adherance to a carbohydrate-restricted diet (5) . Whether a low-or noncaloric sweetener actually helps in weight reduction is also felt to be questionable. However, there have been a few studies in which covert use of noncaloric sweeteners has been associated with a drop in caloric intake (6, 7) . Many studies also cite a psychological benefit of noncaloric sweeteners in weight-reduction programs. This claim has not been substantiated but seems to make good sense.
PA. CRAPO
Despite the lack of research demonstrating a definite benefit for dietary adherance or for weight reduction, many educators feel that the availability of alternative sweeteners is beneficial, even if only for psychological reasons; i.e., the patient feels that he/she can follow a diet better with an alternative source of sweetness (8) .
Note that questions have been raised in recent years about whether the avoidance of sucrose really facilitates metabolic control (9) (10) (11) (12) (13) (14) . Nevertheless, most clinicians and health professionals, as well as official American Diabetes Association policy (15) , recommend some degree of limitation of sucrose in the diet. In addition, there are various reasons, not always directly related to diabetes, why an individual might choose to use an alternative sweetener. These include the desire or need to increase the micronutrient and/or fiber level of the diet for a particular calorie level while maintaining palatability, to decrease the incidence of dental caries, to control serum lipid levels, and even, for some, to improve taste.
AVAILABLE ALTERNATIVE SWEETENERS
Several alternative sweeteners are available for use by individuals with diabetes. They are generally categorized as caloric (nutritive) or noncaloric (nonnutritive) ( Table 1) .
IDEAL ALTERNATIVE SWEETENER
The ideal alternative sweetener for diabetes would not raise blood glucose levels, would taste good, would be easy to use, would be inexpensive, would have the right consistency for various food uses, would be chemically stable, would have minimal or no side effects, would not raise blood lipid levels, would be completely safe, and would contain no calories. Unfortunately, none of the available sweeteners meet all of these criteria. There is no preferred sweetener. Consequently, the health Although aspartame is chemically caloric (or nutritive), it is -200 times as sweet as sucrose, so very little is required to attain equivalent sweetness. Thus, when used in manufactured products (as NutraSweet), it contributes virtually no calories. For pourable tabletop use (Equal), it is packaged with a buffer, such as dextrose or lactose, which provides small amounts of calories.
professional must have a clear understanding of the advantages and disadvantages of each sweetener alternative and must examine and assess the life-style, dietary patterns, and potential risks of individuals so that advice can be tailored to specific needs and concerns.
CALORIC SWEETENERS
Fructose. Fructose (levulose or fruit sugar) is a common monosaccharide in nature, found in its free form in honey, in fruit and other plants, and in combined form as half of the disaccharide sucrose. It traditionally was scarce, but technological advances in the late 1960s and early 1970s made large-scale economical production possible, and fructose is now being marketed more actively.
Fructose probably is the sweetest of the naturally occurring sugars, being -1.0-1.8 times as sweet as sucrose (16) . The actual sweetness depends on the concentration, pH, and temperature of the tasting medium. It is sweeter when cool, dilute, and at a more acidic pH (17) . Even though its caloric content is the same as other nutritive sugars (4 kcal/g), fructose provides the possibility of caloric reduction at equal sweetness because of its great sweetening potential. However, when Hardy et al. (18) incorporated fructose into sugar cookies, white cake, and vanilla pudding, it was not determined to be sweeter than sucrose, and indeed sucrose was frequently ranked significantly sweeter than fructose (18) . When they decreased the sugar level in these products, flavor and overall acceptance ratings also decreased. Thus, when fructose is incorporated into mixed foods, the theoretically potential caloric reduction is not always achieved. Still, in specific food applications, caloric savings can be accomplished. The caloric savings are not usually as great, however, as those achievable by foods formulated with noncaloric sweeteners (such as aspartame or saccharin).
Foods sweetened experimentally with pure crystalline fructose resulted in significantly lower serum glucose and insulin responses than sucrose-sweetened products in adults with type II diabetes (19) . However, pure crystalline fructose is expensive, so manufacturers usually use one of the high-fructose corn syrups (HFCSs) containing varying amounts of fructose (42, 55, or 90%) , the remaining carbohydrate predominantly being glucose with a small percentage of higher saccharides (20) . HFCSs supplied for a study as 90% fructose had an effect on blood glucose similar to that of sucrose (21, 22) . However, analysis of the syrup indicated that it was only 75.8% fructose. Although difficult to explain, the study results indicate that HFCSs with a fructose-to-glucose ratio of 75:25 are unlikely to differ from sucrose (with a fructose-to-glucose ratio of 50:50) in terms of blood glucose effect. Thus, there may be no benefit of a food sweetened with an HFCS compared with a food sweetened with a noncaloric sweetener that has no glucoseraising effect or extra calories.
Fructose is absorbed from the intestine more slowly than glucose (23) and then predominantly and rapidly is taken up and metabolized in the liver (24) . It enters the cell and is metabolized independently of insulin to the triose phosphate and, subsequently, via glyconeogenesis to glycogen. In the absence of adequate insulinization, the trioses enter the gluconeogenic pathway to form glucose. Therefore, in insulin deficiency, increased glucose production can result from these trioses, whereas in treated diabetic and nondiabetic individuals, little gluconeogenesis from fructose occurs (25) . Acutely, fructose has less influence on blood glucose level than does glucose, sucrose, HFCSs, or many complex carbohydrates in diabetic and nondiabetic individuals (26) (27) (28) (29) . However, when basal plasma glucose levels exceeded 140 mg/dl in one study, fructose caused postprandial plasma glucose excursions comparable to those with sucrose or HFCS (22) . In another study of subjects with basal plasma glucose levels >140 mg/dl, fructose maintained a significantly lower blood glucose response than glucose and sucrose, although it was increased compared with blood glucose response to fructose in nondiabetic subjects and subjects with impaired glucose tolerance (29) . Fructose also has a smaller influence on insulin secretory response than does glucose or sucrose (27, 29, 30) .
Pelkonen et al. (31) found no change in fasting blood glucose, glycosuria, or diurnal blood glucose levels in adult type I (insulin-dependent) diabetic patients when 75 g of starch was replaced by fructose for several weeks, regardless of whether diabetes control was excellent or poor at the beginning of the experiment. Crapo et al. (32) found reduced postprandial hyperglycemia to an oral glucose challenge and to fructose-containing meals compared with sucrose-containing meals after 14 days of fructose feeding in the diet of type II diabetic individuals without change in insulin response. Type I diabetic subjects did not have a change in glycosuria when fructose (1.5 g/kg body wt) was substituted for starch for two separate 1-wk periods (33) . An earlier study in children had shown no insulin-sparing effects when about half the daily carbohydrate for 5 wk was fructose rather than isocaloric glucose or sucrose (34) . Neither study in youngsters with type I diabetes demonstrated a deterioration in control of diabetes with fructose ingestion, nor was there a marked improvement. It was suggested that fructose in amounts up to 0.5 g • kg" 1 • day" 1 would have no deleterious effects in type I diabetic children in good or fair control, providing the child adhered to a quantitative diet, the fructose was used on an isocaloric basis, and the fructose was used with parental supervision (33) .
Other questions about the use of fructose are also raised. Serious side effects of fructose are seen when fructose is administered intravenously at high doses. However, there are no significant side effects, e.g., increased blood levels of urea, lactate, pyruvate, or bilirubin, seen after oral ingestion of fructose (32, 35, 36) . Large (>50 g) single oral doses of fructose may lead to diarrhea or gastrointestinal symptoms in some individuals (37) .
Another, potentially adverse, side effect of fructose is its effect on triglyceride levels. It has been implicated as the component of sucrose responsible for elevation of plasma triglycerides (38, 39) , and this suggestion has been supported by studies in animals and in hypertriglyceridemic (32, 40, 41) , hyperinsulinemic (42), diabetic (43) , and normal (44) subjects, in which fructose feeding (40-300 g/day) led to hypertriglyceridemia. Other studies have found that ingestion of fructose (33-154 g/day) in normal (35, 36, 45) , diabetic (44) , and hypertriglyceridemic (46) subjects did not produce an increase in fasting triglyceride level. It has been suggested that the hypertriglyceridemic effect of dietary carbohydrate is mild and temporary in nature and that triglyceride levels will return to baseline levels with time (46) (47) (48) . Longer-term studies of fructose feeding are needed to confirm this. Until such evidence is available, fructose ingestion in subjects with preexisting hypertriglyceridemia should be approached with some caution and monitoring. No increases in cholesterol levels have been reported after fructose feeding in humans except in hyperinsulinemic subjects. Sorbitol and mannitol. Sorbitol and mannitol are polyalcohols, or sugar alcohols, obtained commercially from the reduction of either glucose or fructose. Both occur naturally in plants and have sweetening effects similar to that of glucose and about half that of sucrose (16) . Each contains 4 kcal/g, the same amount as the hexoses for which they might be substituted. They are absorbed slowly from the gastrointestinal tract (49) and have less influence on blood glucose and insulin levels than glucose, sucrose, or fructose. They are rapidly taken up and converted to fructose in the liver. In insulin deficiency, sorbitol and mannitol can be converted to glucose. The slow passive absorption of sorbitol and mannitol can cause osmotic diarrhea, abdominal gas, discomfort, and malabsorption even with relatively low oral doses (usually stated as 30-50 g, although some individuals have tolerance levels as low as 10 g). This effectively limits consumption. Their low level of sweetness also limits their usefulness. Diabetic children have been shown to tolerate dietary sorbitol (as much as 41 g/day in divided doses), with only minor intestinal symptoms in a few of the children, with no increase in blood glucose levels or glycosuria, and with no increase in insulin requirements (50) .
Note that dietary or exogenous sorbitol does not accumulate in the lens or any other body tissue. Absorbed exogenous sorbitol and other sugar alcohols are removed from the blood and metabolized by the liver. In addition, even when high plasma levels of sorbitol are achieved, there is poor diffusibility of the sugar alcohols into cells of the lens or through other biologic membranes (51) . Xylitol. Xylitol is a naturally occurring sugar alcohol that is obtained by hydrogenation of xylose, which is produced from xylan-containing plant materials. It is a palatable sweetener with a sweetness equivalency similar to fructose in an aqueous solution. Like fructose, its 176 DIABETES CARE, VOL. 1 1 , N O . 2, FEBRUARY 1988 sweetness varies with changes in physical state, i.e., reduced by warming or by addition of fruit acids. Like the other sugar alcohols, it contains ~4 kcal/g but is slowly absorbed (52) , resulting in little influence on blood glucose and insulin levels. The slow absorption of xylitol can be a disadvantage (as it is with sorbitol and mannitol), because osmotic diarrhea and flatulence may occur after administration of doses in the range of 30-40 g. When given in incremental doses over a period of weeks, xylitol has been shown to be tolerated at levels of up to 90 g/day (53, 54) . No significant side effects, e.g., increased blood levels of urea, lactate, insulin, pyruvate, triglycerides, or bilirubin, have been shown to occur after oral administration (35) . Total or partial replacement of sucrose by xylitol has been shown to markedly reduce dental caries (55) ; therefore xylitol has a preferred use in foods that are sticky and adhere to teeth and thus are likely to be more cariogenic. This sugar has been successfully used in Scandinavian countries in chewing gums. However, chronic intake of xylitol in animals has been shown to be associated with tumor induction and other pathology. Consequently, use of xylitol is currently curtailed in the United States, and no recommendation concerning its use can be made.
Diabetes educators should be aware that foods formulated with sugar alcohols may contain energy values equal to or greater than that of a nondietetic counterpart. To achieve the same smooth texture in dietetic cookies, ice cream, chocolate, and candies as that of comparable products, manufacturers may need to increase fat content. In addition, because of their low level of sweetness, greater quantities of sorbitol or mannitol may be needed in certain products to achieve equivalent sweetness. Either way, the effect is one of increasing the caloric content of the final product. Whereas sorbitol and mannitol are acceptable sweeteners for individuals with diabetes, there are other sweetners that offer equivalent advantages without as many disadvantages. Thus, the sugar alcohols are not the sweeteners of choice.
NONCALORIC SWEETENERS
Aspartame. Aspartame is actually a nutritive protein sweetener produced commercially from two amino acids, the methyl ester of L-phenylalanine and L-aspartic acid. It is marketed under the trade name NutraSweet in food products and Equal as a tabletop sweetener by the manufacturer (Searle). It was approved by the Food and Drug Administration (FDA) for use as a food additive in 1981 and for use in other products, including soft drinks, in 1983. It is digested as a protein, and like other proteins provides 4 kcal/g (56) . Because it is 180-200 times sweeter than sucrose, only very small amounts are needed to achieve equivalent sweetness, and consequently its caloric contribution to a food is usually minute and insignificant. Aspartame is more expensive (4-5 times) than saccharin but has a taste considered to be excellent (57) . It is not a universal sugar substitute because it breaks down with prolonged heating into its constituent amino acids with resulting loss of sweetness. Consequently, it cannot be used in food applications requiring prolonged heat unless special procedures are employed, such as adding it after heating. Although relatively stable in solid form, aspartame has poor stability in liquids (58); therefore, liquid foods containing aspartame must be carefully formulated and stored. Aspartame cannot be used in recipes that require a bulk of sugar unless other functional compensations are made.
Aspartame does not alter glycemic control of diabetes (59) . The main concerns that have been raised about the use of aspartame have been those of safety. Individuals with diabetes are not felt to differ in this regard from individuals without diabetes. Safety has not been established for individuals <2 yr old, but use should be minimal in this age group. The basic safety concerns are outlined below.
1. Various mild nonspecific symptoms, including dizziness, headache, and menstrual irregularities, have been associated with ingestion of aspartame (60) . No scientific evidence to date suggests that such episodes are anything but coincidental. After evaluation of >500 complaints, the Centers for Disease Control (CDC; 60) ruled that data did "not provide evidence for the existence of serious, widespread, adverse health consequences attendant to the use of aspartame" and it is unlikely that the results of diabetic individuals would differ in this regard. The reported symptoms were mild and were common in the general population. This report did not rule out the possibility that certain individuals might have an unusual sensitivity to the aspartamesweetened products.
2. Biproducts of metabolism of aspartame, methanol, and diketopiperazine are toxic. About 10% by weight of aspartame is converted to methanol, which occurs either before consumption through improper storage of an aspartame-sweetened product or internally during metabolism of aspartame (58) . Either way, the dose of methanol is the same. If conversion occurs before ingestion, the result is a marginally acceptable, but not unsafe, product. Other foods (fruits, vegetables, beer, and wine) are also sources of methanol in the diet in amounts equal to or greater than those seen with significant aspartame use. Whereas few data are available on methanol toxicity, it appears to be due to formaldehyde, which is formed while methanol is metabolized and is converted to formic acid, leading to accumulation of formates (61) . Clinical studies have found no measurable blood levels of methanol with loading doses of aspartame at the projected 99th-percentile exposure level of 34 mg/kg (62) . Abuse doses of 200 mg/kg of aspartame have not been shown to increase blood formate concentrations over predosing levels (62) . The FDA has concluded that there is no cause for concern from the levels of dietary methanol resulting from the highest projected levels of aspartame ingestion. Any concern of the possible toxic effects of diketopiperazine were eliminated by long-term animal studies (63) .
3. Aspartame might alter brain neurotransmitter ac-tivity resulting in functional or behavioral changes. It has been suggested that when aspartame is ingested in conjunction with a high-carbohydrate diet, neurochemical changes due to the elevation of aromatic amino acids, including phenylalanine, may lead to behavioral changes, particularly in children (64) . Aspartame intake in rats at doses of 200 mg/kg body wt significantly increases brain phenylalanine and tyrosine levels (precursors of adrenergic neurotransmitters such as norepinephrine and dopamine; 65,66) while decreasing brain levels of leucine, isoleucine, and valine. Simultaneous ingestion of carbohydrate has been reported to potentiate these effects while blocking the increases in brain tryptophan, 5-hydroxyindoleacetic acid, and serotonin normally seen after a carbohydrate meal (65) . Recent studies have found significant increases in neurotransmitter concentrations in critical brain regions (particularly the hypothalamus) rich in neurotransmitters after aspartame ingestion at levels of 130 and 650 mg/kg body wt by mice (67), although previous studies had found no apparent alteration in whole-brain concentrations of neurotransmitters in rats fed aspartame at levels up to 200 mg/kg body wt (66) . These issues were considered before the approval of aspartame for use in carbonated beverages. After reviewing all of the available data, the FDA concluded that, although aspartame increased plasma and brain phenylalanine levels, there was no evidence that aspartame, either alone or in combination with dietary carbohydrates, altered neurotransmitter activity or behavior (68). 4. Aspartame use might lead to brain tumors or neurotoxicity. In keeping with the requirements of the FDA, data from chronic feeding studies in mice and rats were submitted to the FDA (69, 70) , and the FDA commissioners concluded that aspartame and its products do not contribute to brain tumor formation in rats (71) . The possibility that the amino acids phenylalanine and aspartic acid, either alone or in combination with glutamate, might result in brain damage, mental retardation, or endocrine dysfunction has also been reviewed. Such neurotoxicity had been shown for glutamate, which like aspartate is a dicarboxylic amino acid, and the effects of glutamate and aspartate may be additive. Glutamate is in widespread use in food, particularly as monosodium glutamate (MSG). Toxicity has been demonstrated primarily in mice (72, 73) ; in normal humans, controlled studies of aspartame alone and aspartame plus MSG ingestion at expected and abuse levels of consumption showed no effect of aspartame on plasma concentrations of aspartate and glutamate beyond those arising from MSG contained in the meals themselves (74) (75) (76) (77) (78) . The FDA concluded there is no evidence that the ingestion of aspartame, either alone or together with glutamate, contributes to brain damage or dysfunction of neuroendocrine regulatory systems (71).
5. Long boiling of aspartame produces an "unnatural" version of aspartame. In this process, known as amino acid racemization, the amino acids are converted to their d-isomers (79) . No one knows the potential health consequences of ingesting this altered form of the chemical. However, the major use problem of aspartame is that it loses sweetness when heated and should not be subjected to long-term boiling. The only practical implication is that of educating the public about the proper handling and storage of aspartame.
6. Harm to people with inherited phenylketonuria (PKU). Sustained plasma levels of phenylalanine resulting in PKU are associated with mental retardation. The question was raised initially as to whether aspartame use could raise plasma phenylalanine levels sufficiently to cause mental retardtion similar to that seen in PKU. Clinical studies demonstrated, however, that aspartame use could not be expected to increase the incidence of the form of mental retardation associated with sustained elevation of plasma phenylalanine levels (71, (74) (75) (76) (77) (80) (81) (82) (83) . It was concluded that the marketing of aspartame would not create any additional risk to PKU children not on a restricted diet, individuals heterozygous for PKU, undetected cases of PKU, or pregnant women with the special condition hyperphenylalaninemia (71) .
The FDA has set 50 mg/kg body wt as an acceptable daily intake (ADI) for aspartame. This is -1 % of an amount shown in animals to have no toxic effects. (The Canadian and FAO/WHO ADI is set at 40 mg/kg.) Thus, the ADI indicates that an intake of aspartame at 50 mg • kg" 1 body wt • day" 1 over a lifetime is considered safe by a factor of at least 100-fold. For a 50-kg individual, an ADI of 50 mg/kg represents 12 12-oz cans of 100% aspartame-sweetened soda or -6 2 cans of soda sweetened with a blend of aspartame plus saccharin (Table 2) . One packet of Equal granulated sweetener contains 35 mg of aspartame, which is equivalent in sweetness to 2 tsp of sucrose. An ADI of 50 mg/kg would allow 71 packets of Equal for the 50-kg individual. It has been estimated that 34 mg/kg (equivalent to ~1 Equal packet/kg body wt) represents the 99th percentile of the projected intake for an entire day when aspartame replaces all dietary sucrose and saccharin on a sweetness basis (71) . Because aspartame cannot replace all sources of dietary sucrose and saccharin, this estimate represents an exaggerated estimate of intake, and consumption figures remain well below the acceptable daily intake level.
In summary, aspartame has been determined and reaffirmed in ongoing evaluation by the FDA and other regulatory agencies to be safe for healthy adults, lactating or pregnant women, children and adolescents, and people with diabetes. Saccharin. Discovered in 1897, saccharin was the first man-made sugar substitute. It gained widespread popularity during the sugar shortages of the First and Second World Wars, and when cyclamate was banned in 1970, it became the only available noncaloric sweetener. It is 300-400 times as sweet as sucrose and has essentially no caloric value, but it does have a bitter aftertaste found to be objectionable by some people. It is the least expensive of the alternative sweeteners and can be used in cooking, although it does not provide the functional (bulk) qualities of the caloric hexoses. In April 1977, the FDA proposed a ban on saccharin as a food additive because it had been found to cause urinary bladder cancer in experimental animals. The major scientific evidence for the proposed ban were two-generation studies in rats, in which the second-generation male animals, exposed to saccharin in utero and throughout remaining life, developed bladder carcinoma at saccharin doses of 5 % (84-86). Because of an intense public response against the proposed ban, Congress instituted a moratorium that postponed the ban for 18 months (Publ. Law 95-203, The Saccharin Study and Labeling Act) to allow for further research and assessment of the issue. This moratorium on the saccharin ban has been extended on four subsequent occasions, the most recent being in April 1985. This legislation required specific warnings on labels of foods containing saccharin stating that "use of this product may be hazardous to your health. This product contains saccharin which has been determined to cause cancer in laboratory animals."
A select committee on sugar substitutes of the American Diabetes Association, chaired by Ronald K. Kalkhoff, MD, reviewed the experimental data on saccharin available through May 1978 and concluded that "based on evidence now available, there appears to be little justification for placing further governmental restrictions on the use of saccharin by the American public at the present time" (87) . Subsequently, additional research evidence from epidemiological studies in humans have found no association between bladder cancer risk and a history of consumption of artificial sweeteners (88) (89) (90) . However, such studies are felt to lack the sensitivity to detect relatively weak carcinogens. Studies in animals have shown dose-response relationships and have confirmed that large doses of saccharin (4-5% or above) are associated with a slightly higher incidence of bladder cancer in male rats than in control animals, even without in utero exposure. The National Academy of Sciences (NAS) concluded in 1978 that saccharin was a carcinogen in animals, although of low potency, and that it was a potential cancer-causing agent in humans (91) . Although there is inadequate evidence to prove that saccharin is not a carcinogen in humans, there is essentially no argument that, if anything, it is a very weak carcinogen. Current food laws do not require a determination of benefit or efficacy of alternative sweeteners, and essentially no studies are available. In the past, the FDA's interpretation of the Delaney Clause of the 1958 Food Additives Amendment to the Federal Food, Drug, and Cosmetic Act of 1938 has been strict. The amendment states that "no additive shall be deemed to be safe if it is found to induce cancer, when ingested by man or animal. . . ." In the past few years, the FDA's interpretation of the Delaney Clause appears to be changing, moving to the calculation and assessment of quantitative risk. Public interest groups continue to argue, however, that no level of risk is acceptable, particularly when an alternative is available.
Subjects who may be at higher-than-normal risk from artificial-sweetener ingestion include children and pregnant women, because the effective dose to the child or fetus may be greater than in other groups. There is no evidence, however, of harm to the fetus from maternal saccharin ingestion. Because other alternative sweeteners are available, the consumer has a personal choice. Safe limits of intake of saccharin have not been defined by the FDA. The ADI suggested by the FAO/WHO is 0-2.5 mg/kg, which is only achievable when other alternative sweeteners are also available. Previous GRAS (Generally Recognized As Safe) list recommendations (1955) were for limitations of saccharin to 0.5 g/day in children and ~1 g/day in 70-kg adults (National Academy of Sciences/National Research Council, NAS/NRC). [One teaspoon of packeted pourable saccharin (which includes a carrier) contains in the range of 14-20 mg of saccharin.] Recommended limitations on daily intake of saccharin should be developed. Cyclamates. Cyclamate was discovered in the 1940s, and because it lacked the bitter aftertaste of saccharin, DIABETES CARE, VOL. 1 1 , N O . 2, FEBRUARY 1988 it became widely used in the United States, particularly in soft drinks. In 1970, however, on the basis of a report from rat studies that large doses (given with saccharin, 10:1) were associated with increased risk of bladder cancer (92) , cyclamate use was banned by the FDA. On more than one occasion, Abbott Laboratories has petitioned the FDA to reassess the status of cyclamates. Most recently, in response to a 1982 petition, the Cancer Assessment Committee of FDA reviewed all cyclamate data and concluded that the collective weight of the many experiments intending to discriminate between the carcinogenicity and noncarcinogenicity of cyclamate indicate that cyclamate is not carcinogenic (93) . A committee on carcinogenicity of cyclamates was then established by the NAS/NRC at the request of the FDA to study the question. This committee also concluded that cyclamate did not cause cancer but suggested that the FDA conduct further research to rule out the possibility that cyclamate could promote cancer when used with saccharin or other substances. The FDA is now evaluating that possibility as well as reports that the sweetener is associated with testicular atrophy and chromosomal damage. Although cyclamate continues to be available in Canada, no recommendations can be made for its use in the U.S. because it is still banned. Its availability would provide consumers with an additional sweetener choice, one that was well accepted by the public before its ban.
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DISCUSSION
I
n conclusion, there is insufficient scientific information to determine whether alternative sweeteners are of value in the management of diabetes, either in improving dietary adherance or in contributing to the achievement or maintenance of a lower body weight. Despite this uncertainty about the efficacy of their use in dietary treatment, alternative sweeteners are widely advocated and used. Consequently, the health professional must be prepared to provide advice about their use. Of the available alternative sweeteners, none is preferred. Each has advantages and disadvantages. Recommendations about alternative-sweetener use should therefore be tailored to the specific dietary and life-style patterns and concerns of the individual. Research needs. /) Does use of alternative sweeteners contribute to diabetes control and/or to the achievement and/or maintenance of lower body weight in obese people? 2) What are the risks and metabolic effects of long-term individual and combination alternative sweetener use in humans, particularly in individuals with diabetes because their intake of alternative sweeteners as a group may be greater than population means? 3) Do glucose and sucrose need to be restricted in the diets of individuals with diabetes in comparison with the diets of the nondiabetic population?
